HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage.

Abstract
In the study, the cytotoxicity and genotoxicity of aclarubicin (ACL) against A549 (human non-small cell lung adenocarcinoma) and HepG2 (human hepatocellular carcinoma) cell lines were evaluated and compared with that of doxorubicin (DOX). The effect of both anthracyclines in combination was also investigated. In order to get a deeper insight into the effectiveness of the drugs and their combination, their effects on the DNA damage and distribution of the cell cycle of A549 and HepG2 cells were investigated. After treatment with investigated compounds, apoptotic and necrotic morphological changes were estimated by double staining cells with orange acridine and ethidium bromide. The results showed that ACL was much more cytotoxic against lung (A549) and liver (HepG2) cancer cell lines than DOX. However, the drugs affected the cell cycle differently. ACL arrested cells in the G1 phase, while DOX arrested them in the G2/M phase. DOX and ACL at high concentrations are able to trigger apoptosis in both A549 and HepG2 cells. When the drugs were used in combination, subtoxic concentrations of ACL antagonized the cytotoxic effects of doxorubicin. Pre-incubation of cells with subtoxic concentrations of ACL reduced the level of DNA damage by DOX but increased DOX genotoxicity in the presence of verapamil.
AuthorsArkadiusz Gajek, Aneta Rogalska, Aneta Koceva-Chyła
JournalToxicology in vitro : an international journal published in association with BIBRA (Toxicol In Vitro) Vol. 55 Pg. 140-150 (Mar 2019) ISSN: 1879-3177 [Electronic] England
PMID30579959 (Publication Type: Journal Article)
CopyrightCopyright © 2018 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibiotics, Antineoplastic
  • Aclarubicin
  • Doxorubicin
Topics
  • A549 Cells
  • Aclarubicin (pharmacology)
  • Antibiotics, Antineoplastic (pharmacology)
  • Cell Cycle (drug effects)
  • Cell Survival (drug effects)
  • DNA Damage (drug effects)
  • Doxorubicin (pharmacology)
  • Hep G2 Cells
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: